Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Toronto

$135,000.00

Manipulating the Microbiome to Prevent Multiple Sclerosis Progression

FY 2023-24

Summary
Multiple sclerosis (MS) is a chronic disease affecting approximately 90,000 Canadians and more than 2.5 million people worldwide. It occurs when the body's immune system attacks myelin, the protective coating that helps neurons communicate. Surprisingly, evidence suggests that MS, and other neurological disorders, can be influenced by the gut microbiota - the trillions of bacteria, viruses, and other microbes that live within our gastrointestinal tracts. These microbes are important for healthy development and functioning of the brain and immune system, but how and why is poorly understood. Our laboratory has recently discovered that gut microbiota from elderly humans transferred into young mice can worsen a model of MS progression - showing that microbiota can modify MS-like disease worsening. Our goal for this study is to determine which microbes influence MS progression and identify how they do this. We will collect gut microbiota from people with MS whose disease is progressively worsening and from other people with MS who have stable disease. We will then transplant these microbial communities into our mouse model of progressive MS. We expect to see that microbiota from people with stable MS will protect against progression in our model, while microbiota from people with progressive MS will worsen disease. We will then identity which microbes and their byproducts are responsible for disease modification. Finally, we will design therapies to replicate the protective effects of microbes. There is currently no effective medication to prevent people living with MS from progressing into more severe disease. Here, we aim to uncover how the microbiota can protect against MS progression. Our ultimate goal is to translate this research into microbe-based therapeutics to improve the health of Canadians living with MS.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
492455
Name
Champagne-Jorgensen Kevin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Manipulating the Microbiome to Prevent Multiple Sclerosis Progression
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bacteriophage; Cerebrospinal Fluid; Extracellular Vesicles; Fecal Microbiome Transplant; Microbiome; Microbiota-Gut-Brain Axis; Multiple Sclerosis; Neuroimmunology; Progressive Multiple Sclerosis; Proteomics
Abstract
Multiple sclerosis (MS) is a chronic disease affecting approximately 90,000 Canadians and more than 2.5 million people worldwide. It occurs when the body's immune system attacks myelin, the protective coating that helps neurons communicate. Surprisingly, evidence suggests that MS, and other neurological disorders, can be influenced by the gut microbiota - the trillions of bacteria, viruses, and other microbes that live within our gastrointestinal tracts. These microbes are important for healthy development and functioning of the brain and immune system, but how and why is poorly understood. Our laboratory has recently discovered that gut microbiota from elderly humans transferred into young mice can worsen a model of MS progression - showing that microbiota can modify MS-like disease worsening. Our goal for this study is to determine which microbes influence MS progression and identify how they do this. We will collect gut microbiota from people with MS whose disease is progressively worsening and from other people with MS who have stable disease. We will then transplant these microbial communities into our mouse model of progressive MS. We expect to see that microbiota from people with stable MS will protect against progression in our model, while microbiota from people with progressive MS will worsen disease. We will then identity which microbes and their byproducts are responsible for disease modification. Finally, we will design therapies to replicate the protective effects of microbes. There is currently no effective medication to prevent people living with MS from progressing into more severe disease. Here, we aim to uncover how the microbiota can protect against MS progression. Our ultimate goal is to translate this research into microbe-based therapeutics to improve the health of Canadians living with MS.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Champagne-Jorgensen, Kevin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
University of Toronto - $135,000 Grant (2023-24) | Canada Spends